Immune
Simcere Zaiming Pharmaceutical Co. Ltd., a subsidiary of Simcere Pharmaceutical Group Ltd., has entered into an exclusive global licensing agreement with F. Hoffmann-La Roche Ltd. for the development and commercialization of SIM-0660, a trispecific antibody with therapeutic potential across B-cell-mediated diseases.